Four years ago, almost no one had heard of it. Today, Herceptin is a household name and women with early-stage breast cancer are going to court for the right to get it. Yet the drug is not actually licensed for use in early-stage cancer - and the clinical tests, while promising, don't yet prove it will ever save lives. How did Herceptin become a cause celebre? Sarah Boseley investigates.